“CSR can offer benefits to firms in many ways, including greater attractiveness of the firm to its employees, advertising and improved pricing power with customers, and insurance from activists. My research with Po-Hsuan Hsu at University of Hong Kong has focused on how corporate philanthropy can benefit pharmaceutical innovation,” says Fred Bereskin, Assistant Professor of Finance at the Alfred Lerner College of Business & Economics at the University of Delaware. Bereskin’s focus is on corporate finance, particularly innovation and corporate governance, and he says that pharmaceutical firms are some of the most generous, in terms of their philanthropy; however, not all companies understand how philanthropy can ultimately benefit innovation and help develop partnerships with outside organizations. For one thing, collaborations with academic and not-for-profit organizations can include licensing deals that result in valuable patents. One common model in big pharma is to establish a research institute; the Center for Advanced Cellular Therapeutics created by Novartis and the University of Pennsylvania in 2012, for example. The center was partly funded by a $20-million grant from Novartis – and demonstrates how a direct donation can benefit innovation (as well as patients in need of cell therapies).
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
If you don’t have an account you can:
REGISTER NOW – it’s FREE and always will be!
You will benefit from:
- Unlimited access to ALL articles including White Papers
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login as a Guest or via Social Media
This will allow you to read this article but you will only have limited access to The Medicine Maker.Login as Guest Twitter LinkedIn Google+ Facebook